180 related articles for article (PubMed ID: 22361690)
1. Rituximab and mycophenolate combination therapy in refractory dermatomyositis with multiple autoimmune disorders.
Parziale N; Kovacs SC; Thomas CB; Srinivasan J
J Clin Neuromuscul Dis; 2011 Dec; 13(2):63-7. PubMed ID: 22361690
[TBL] [Abstract][Full Text] [Related]
2. [Refractory dermatomyositis associated with chronic organizing pneumonia treated with rituximab: report of one case].
Yáñez V J; Cisternas M M; Saldías H V; Saldías P F
Rev Med Chil; 2009 Jan; 137(1):88-93. PubMed ID: 19399327
[TBL] [Abstract][Full Text] [Related]
3. [Autoimmune myelofibrosis with dermatomyositis].
Sahali S; Ghosn J; Lazure T; Goujard C; Delfraissy JF; Lambotte O
Rev Med Interne; 2009 Jan; 30(1):71-3. PubMed ID: 18508162
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil therapy for juvenile dermatomyositis with immune thrombocytopenic purpura.
Ogimi C; Honma N; Tanaka R; Oh-ishi T
Mod Rheumatol; 2012 Apr; 22(2):280-3. PubMed ID: 21710356
[TBL] [Abstract][Full Text] [Related]
5. [Remission maintenance with methotrexate, azathioprine or mycophenolate-mofetil after induction therapy with rituximab for granulomatosis with polyangiitis].
Hellmich B
Z Rheumatol; 2015 Mar; 74(2):157-8. PubMed ID: 25524229
[No Abstract] [Full Text] [Related]
6. Rituximab as a first-line agent for the treatment of dermatomyositis.
Haroon M; Devlin J
Rheumatol Int; 2012 Jun; 32(6):1783-4. PubMed ID: 20340018
[TBL] [Abstract][Full Text] [Related]
7. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients.
Kasperkiewicz M; Shimanovich I; Meier M; Schumacher N; Westermann L; Kramer J; Zillikens D; Schmidt E
Br J Dermatol; 2012 Jan; 166(1):154-60. PubMed ID: 21910700
[TBL] [Abstract][Full Text] [Related]
8. Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin.
Shahani L
BMJ Case Rep; 2012 Aug; 2012():. PubMed ID: 22907859
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil in dermatomyositis: is it safe?
Rowin J; Amato AA; Deisher N; Cursio J; Meriggioli MN
Neurology; 2006 Apr; 66(8):1245-7. PubMed ID: 16636243
[TBL] [Abstract][Full Text] [Related]
10. Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report.
Bruserud Ø; Håvardstein K
Hematology; 2009 Aug; 14(4):224-6. PubMed ID: 19635186
[TBL] [Abstract][Full Text] [Related]
11. Rituximab treatment in patients with refractory inflammatory myopathies.
Mahler EA; Blom M; Voermans NC; van Engelen BG; van Riel PL; Vonk MC
Rheumatology (Oxford); 2011 Dec; 50(12):2206-13. PubMed ID: 21571768
[TBL] [Abstract][Full Text] [Related]
12. A case of Wong-type dermatomyositis treated with rituximab and IVIG.
Argobi Y; Fedeles F; Schoenfeld SR
Australas J Dermatol; 2021 Feb; 62(1):e86-e87. PubMed ID: 32671816
[TBL] [Abstract][Full Text] [Related]
13. Rituximab as therapy for refractory polymyositis and dermatomyositis.
Noss EH; Hausner-Sypek DL; Weinblatt ME
J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post-hematopoietic stem cell transplant for dyskeratosis congenita due to TINF2 mutation.
O'Connell N; Goodyer M; Gleeson M; Storey L; Williams M; Cotter M; O'Marcaigh A; Smith O
Pediatr Transplant; 2014 Feb; 18(1):E22-4. PubMed ID: 24168326
[TBL] [Abstract][Full Text] [Related]
15. Co-occurrence of dermatomyositis and Hashimoto's thyroiditis in a type I diabetic patient.
McClanahan CM; Smith HL; Garner SA
QJM; 2015 Apr; 108(4):331-3. PubMed ID: 23033498
[No Abstract] [Full Text] [Related]
16. Therapy of polymyositis and dermatomyositis.
Marie I; Mouthon L
Autoimmun Rev; 2011 Nov; 11(1):6-13. PubMed ID: 21740984
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in the treatment of refractory dermatomyositis.
Chiappetta N; Steier J; Gruber B
J Clin Rheumatol; 2005 Oct; 11(5):264-6. PubMed ID: 16357773
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis.
Edge JC; Outland JD; Dempsey JR; Callen JP
Arch Dermatol; 2006 Jan; 142(1):65-9. PubMed ID: 16415388
[TBL] [Abstract][Full Text] [Related]
19. Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab.
Sharma AP; Filler G
Pediatr Nephrol; 2009 Feb; 24(2):423-4. PubMed ID: 18853197
[No Abstract] [Full Text] [Related]
20. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
